Provided is compound
racanisodamine eye drops prepared from the following raw materials: 0.010-0.02 wt% of
racanisodamine, 0.005-0.01 wt% of tropicamide, 1.5-2.8 wt% of
sodium chondroitin sulfate, 0.05-0.4 wt% of
diclofenac sodium, 0.05-0.15 wt% of a
recombinant human epidermal growth factor, 0.72-1.25 wt% of
sodium chloride, 0.005-0.012 wt% of thiomersalate, a pH
regulator for adjusting pH to 5.5-6.5, and the balance being injection water. The compound
racanisodamine eye drops disclosed by the invention are applied to adolescents, children and adults who often use eyes at a
short distance, sothat the delaying and preventing effects on myopia of the adolescents and children are more obvious and effective after the compound racanisodamine eye drops are dripped for a long time, and for adults, visual fatigue can be significantly improved, and the
elimination of eyeball discomfort and other symptoms can be accelerated;
diclofenac sodium and racemic
anisodamine are combined to achieve a good synergistic effect,
diclofenac sodium is used as a ligand and matched with racemic
anisodamine to generate a synergistic effect of
biological activity, and meanwhile,
diclofenac sodium and racemicanisodamine have the possibility of reducing
toxicity, are low in price and easy to obtain and are worthy of popularization clinically.